|
Neoplasms
|
0.080 |
AlteredExpression
|
group |
BEFREE |
Therefore, the combination of high MAP17 and SGLT1 levels is a marker for good prognosis in patients with cervical tumors after cisplatin plus radiotherapy treatment.
|
23418532 |
2013 |
|
Neoplasms
|
0.080 |
AlteredExpression
|
group |
BEFREE |
In addition, DD96 is overexpressed markedly in various human carcinomas originating from the colon, breast, and lung, as well as in a number of cell lines derived from tumors of these organs compared with normal epithelial cell populations.
|
9815914 |
1995 |
|
Neoplasms
|
0.080 |
AlteredExpression
|
group |
BEFREE |
We have found that MAP17 is expressed in 60% human mammary tumors while it is not expressed in normal or benign neoplasias.
|
22266858 |
2012 |
|
Neoplasms
|
0.080 |
AlteredExpression
|
group |
BEFREE |
In addition, we show that aberrant promoter hypomethylation-associated overexpression of MAP17 might promote tumor growth in thyroid cancer.
|
23666970 |
2013 |
|
Neoplasms
|
0.080 |
AlteredExpression
|
group |
BEFREE |
Fascin-1 and MAP17 are stem cell markers whose excessive expression in tumors is associated with aggressive tumor phenotypes.
|
31273628 |
2019 |
|
Neoplasms
|
0.080 |
AlteredExpression
|
group |
BEFREE |
We show that MAP17 expression is induced during lung tumourigenesis, particularly in lung adenocarcinomas, and provide in vitro and in vivo evidence that MAP17 levels predict sensitivity to therapies currently under clinical use in adenocarcinoma tumours, including cisplatin, carboplatin and EGFR inhibitors.
|
30119639 |
2018 |
|
Neoplasms
|
0.080 |
AlteredExpression
|
group |
BEFREE |
Conversely, MAP17 downregulation in a tumor cell line constitutively expressing this gene led to Notch pathway inactivation and a marked reduction of stemness.
|
28153862 |
2017 |
|
Carcinoma
|
0.070 |
AlteredExpression
|
group |
BEFREE |
MAP17 is a small, 17-kDa, non-glycosylated membrane protein that is overexpressed in a percentage of carcinomas.
|
22266858 |
2012 |
|
Carcinoma
|
0.070 |
AlteredExpression
|
group |
BEFREE |
We identified MAP17, a small 17 kDa non-glycosylated membrane protein previously identified by differential display being over-expressed in carcinomas.
|
17548903 |
2007 |
|
Carcinoma
|
0.070 |
AlteredExpression
|
group |
BEFREE |
MAP17 (PDZK1IP1) is a small, 17 kDa non-glycosylated membrane protein located in the plasma membrane and Golgi apparatus and is overexpressed in a wide variety of human carcinomas.
|
30250642 |
2018 |
|
Carcinoma
|
0.070 |
AlteredExpression
|
group |
BEFREE |
Taken together, our data show an independent activation of MAP17 promoter that can be driven by oncogenes and that might explain the common overexpression of MAP17 in human carcinomas.
|
17426052 |
2007 |
|
Carcinoma
|
0.070 |
AlteredExpression
|
group |
BEFREE |
In addition, DD96 is overexpressed markedly in various human carcinomas originating from the colon, breast, and lung, as well as in a number of cell lines derived from tumors of these organs compared with normal epithelial cell populations.
|
9815914 |
1995 |
|
Carcinoma
|
0.070 |
AlteredExpression
|
group |
BEFREE |
MAP17 is a small nonglycosylated membrane protein that is overexpressed in a high percentage of carcinomas.
|
25837675 |
2015 |
|
Carcinoma
|
0.070 |
AlteredExpression
|
group |
BEFREE |
Using in situ hybridization, we demonstrated that MAP17 and PDZK1 mRNAs are markedly up-regulated in human carcinomas.
|
10496535 |
1999 |
|
Malignant Neoplasms
|
0.030 |
AlteredExpression
|
group |
BEFREE |
MAP17 is aberrantly overexpressed in a number of malignancies.
|
29616128 |
2018 |
|
Malignant neoplasm of breast
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Expression of fascin-1 and MAP17 was assessed via immunohistochemistry in surgical specimens of a cohort comprised of 127 patients with resectable breast cancer.
|
31273628 |
2019 |
|
Neoplasm Metastasis
|
0.020 |
AlteredExpression
|
phenotype |
BEFREE |
Real-time qRT-PCR validation experiment of LCN2 and PDZK1IP1 showed a consistent up-regulation in the metastasis group.
|
22419659 |
2012 |
|
Neoplasm Metastasis
|
0.020 |
AlteredExpression
|
phenotype |
BEFREE |
High MAP17 expression was positively correlated with gender, distant metastasis, early recurrence (≤ 2 year), and serum alpha-fetoprotein (all <i>p</i> < 0.05).
|
29190940 |
2017 |
|
Thyroid carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Quantitative RT-PCR showed that HS6ST2, COL1A1, F2RL1, LEPREL1, PDZK1, and PDZK1IP1 are overexpressed in thyroid carcinoma samples compared with normal thyroids.
|
24848707 |
2014 |
|
Thyroid carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
In addition, we show that aberrant promoter hypomethylation-associated overexpression of MAP17 might promote tumor growth in thyroid cancer.
|
23666970 |
2013 |
|
Breast Carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Expression of fascin-1 and MAP17 was assessed via immunohistochemistry in surgical specimens of a cohort comprised of 127 patients with resectable breast cancer.
|
31273628 |
2019 |
|
Adenocarcinoma
|
0.010 |
AlteredExpression
|
group |
BEFREE |
We show that MAP17 expression is induced during lung tumourigenesis, particularly in lung adenocarcinomas, and provide in vitro and in vivo evidence that MAP17 levels predict sensitivity to therapies currently under clinical use in adenocarcinoma tumours, including cisplatin, carboplatin and EGFR inhibitors.
|
30119639 |
2018 |
|
Malignant neoplasm of thyroid
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
In addition, we show that aberrant promoter hypomethylation-associated overexpression of MAP17 might promote tumor growth in thyroid cancer.
|
23666970 |
2013 |
|
Noninfiltrating Intraductal Carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, the expression of DD96 is induced in immortalized breast ductal epithelial cell lines compared with normal breast ductal epithelial cells, and, in vivo, in premalignant conditions, such as adenoma of the colon and ductal carcinoma in situ of the breast.
|
9815914 |
1995 |
|
Ulcerative Colitis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Certain cancer-related genes such as DD96, DRAL and MXI1 were differentially expressed only in UC.
|
11181568 |
2001 |